Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure

被引：0
|
作者：
Jonathan D. Ravid
Luke J. Laffin
机构：
[1] Cleveland Clinic Foundation,Internal Medicine Residency Program
[2] Cleveland Clinic Foundation,Section of Preventive Cardiology and Rehabilitation, Department of Cardiovascular Medicine
来源：
Current Cardiology Reports | 2022年 / 24卷
关键词：
Finerenone; Mineralocorticoid receptor; Chronic kidney disease (CKD); Hypertension; Albuminuria; Heart failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1251 / 1259
页数：8
相关论文
共 50 条
  • [31] Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
    Palanisamy, Srikanth
    Hernandez, Mario Funes
    Chang, Tara, I
    Mahaffey, Kenneth W.
    CARDIOLOGY AND THERAPY, 2022, 11 (03) : 337 - 354
  • [32] The mineralocorticoid receptor in chronic kidney disease
    Barrera-Chimal, Jonatan
    Jaisser, Frederic
    Anders, Hans-Joachim
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (13) : 3152 - 3164
  • [33] Effects of Non-Steroidal Mineralocorticoid Antagonist (Finerenone) in Western Diet-Induced Kidney Disease
    Myakala, Komuraiah
    Ribeiro, Patricia de Carvalho
    Wang, Xiaoxin
    Korolowicz, Kyle E.
    Rodriguez, Olga C.
    Albanese, Chris
    Levi, Moshe
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 668 - 668
  • [34] Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism
    Epstein, Murray
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (12): : 993 - 1003
  • [35] The Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction In Preclinical Non-diabetic Chronic Kidney Disease
    Posada, Ixchel Lima
    Stephan, Yohan
    Soulie, Matthieu
    Palacios-Ramirez, Roberto
    Bonnard, Benjamin
    Kolkhof, Peter
    Mulder, Paul
    Jaisser, Frederic
    HYPERTENSION, 2023, 80
  • [36] Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes (vol 15, pg 501, 2022)
    Lerma, E. V.
    Wilson, D. J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (11) : I - I
  • [37] Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease
    Watson, Kristin
    Kukin, Alina
    Wasik, Allie K.
    Shulenberger, Christine E.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (06) : 685 - 698
  • [38] Perspective on Nonsteroidal Mineralocorticoid Receptor Antagonism in Diabetic Kidney Disease
    Ghuman, Jasleen K.
    Tuttle, Katherine R.
    KIDNEY360, 2022, 3 (04): : 744 - 748
  • [39] Utilization of the Nonsteroidal Mineralocorticoid Receptor Antagonist (MRA) Finerenone with or without Previous Steroidal MRA
    Zheng Zihe
    Fatoba, Samuel T.
    Novin, Matthew
    Guerrero, German
    Wang Yunxun
    Farag, Youssef M. K.
    Mckee, Connor W.
    Huang Wei
    Tian Hongping
    Singh Rakesh
    Du Yuxian
    Mares, Jon W.
    Lavagnino, Marco
    Rockett, Drew
    Sankaralingam, Karthik
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [40] Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment
    Heinig, Roland
    Kimmeskamp-Kirschbaum, Nina
    Halabi, Atef
    Lentini, Silvia
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (06): : 488 - 501
12345